Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech M&A expected to be a 'different animal' in 2022

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Aug 10, 2022 2:04pm

141 Views

Post# 34885685

RE:RE:RE:RE:RE:RE:RE:RE:RE:Biotech M&A expected to be a 'different animal' in 2022

Noteable wrote: You said you would stop responding to my posts. What's you're problem? Can't keep your word? More of your empty promises? Frustrated by your bad decisions to bet against the rising trend in Big Pharma expected flurry of M&A activities going into the latter H2 '22 ?

It was my last post for you only! Keep your good work my favorite stop clock!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing